Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Submit a comment

Kinetics of rubidium-82 after coronary occlusion and reperfusion. Assessment of patency and viability in open-chested dogs.
R A Goldstein
R A Goldstein
Published April 1, 1985
Citation Information: J Clin Invest. 1985;75(4):1131-1137. https://doi.org/10.1172/JCI111807.
View: Text | PDF
Research Article

Kinetics of rubidium-82 after coronary occlusion and reperfusion. Assessment of patency and viability in open-chested dogs.

  • Text
  • PDF
Abstract

Currently available noninvasive techniques are unable to rapidly assess artery patency and tissue viability during acute myocardial infarction. In prior studies, rubidium-82 (Rb-82), a short-lived positron emitter obtained from a generator, was validated as an indicator of flow with a model that included the rate constants for transfer into and out of the cell. Accordingly, in the current study, 20 open-chested dogs with experimental infarction were studied serially at base line, after coronary occlusion, and at reperfusion. Time-activity curves acquired with beta probes on the epicardial surface were used to measure flow and net transfer of rubidium. Flow decreased to 0.41 +/- 0.08 ml/min per gram during occlusion and increased to 2.73 +/- 0.56 ml/min per gram in potentially viable ischemic tissue, whereas flows were 0.32 +/- 0.08 during occlusion (P less than 0.05 vs. viable) and 1.58 ml/min per gram (P less than 0.002 vs. viable) in irreversibly injured tissue. The transfer rate constant for Rb-82, kT, at base line was +1.22 +/- 0.60 X 10(-3) s-1 and did not change significantly during occlusion in viable vs. nonviable samples (+1.41 +/- 1.27 vs. +0.93 +/- 1.51 X 10(-3) s-1, respectively), except that 4 out of 11 nonviable tissue samples had negative kTs. At reperfusion, viable myocardial samples were all positive (+1.26 +/- 1.58 X 10(-3) s-1), whereas all irreversibly injured tissues had a negative kT, indicating leakage of tracer (-1.50 +/- 1.10 X 10(-3) s-1, P less than 0.001). This study suggests that Rb-82 time-activity curves can be useful to determine patency of an infarct related artery and potential viability after reperfusion during myocardial infarction.

Authors

R A Goldstein

×

Guidelines

The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.

  • Comments appear on the Journal’s website and are linked from the original article’s web page.
  • Authors are notified by email if their comments are posted.
  • The Journal reserves the right to edit comments for length and clarity.
  • No appeals will be considered.
  • Comments are not indexed in PubMed.

Specific requirements

  • Maximum length, 400 words
  • Entered as plain text or HTML
  • Author’s name and email address, to be posted with the comment
  • Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
  • Comments may not include figures
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts